In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

After the failure of TKI therapy in HER2-positive breast cancer, would you prefer an "ADC" or "HP+" regimen? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Xuening Ji from Affiliated Zhongshan Hospital of Dalian University and Dr. Chunfang Hao from Tianjin Cancer Hospital shared their perspectives. Professor Ji advocated for the ADC approach, while Professor Hao supported the "HP+" regimen. Following the session Oncology frontier  invited both experts to elaborate on their viewpoints.
Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

China has historically been a high-prevalence area for Hepatitis B virus (HBV) infection, with a hepatitis B surface antigen (HBsAg) prevalence rate of 9.7% in 1992. Comprehensive strategies, including the hepatitis B vaccine program for newborns (HepB), with a strong emphasis on timely administration of the birth dose and completion of the three-dose schedule, have significantly reduced mother-to-child transmission and early childhood HBV infections. With the significant reduction in the cost of antiviral drugs, treatment accessibility and affordability have greatly improved. From July 20 to 21, the "2024 World Hepatitis Day Campaign and Hepatitis Elimination Action Conference" was held in Beijing. Dr. Jidong Jia from Beijing Friendship Hospital ,Capital Medical University delivered a keynote speech titled "Progress and Challenges in the Prevention and Treatment of Hepatitis B in China," where he systematically explained the progress made, the challenges faced, and the urgent actions needed in the prevention and treatment of hepatitis B in China.
Expert Commentary | Dr. Lin Zhang: Immune Activation as the Foundation for Sustained Efficacy of Yttrium-90 Radioembolization in Liver Cancer

Expert Commentary | Dr. Lin Zhang: Immune Activation as the Foundation for Sustained Efficacy of Yttrium-90 Radioembolization in Liver Cancer

Yttrium-90 (Y90) resin microsphere selective internal radiotherapy (Y90-RE) is a minimally invasive local treatment method that can effectively control tumor progression in hepatocellular carcinoma (HCC) patients who are ineligible for resection or ablation, with compensated liver function and good overall condition. With the advancement of precision medicine, the clinical understanding of immune activation by Y90-RE has deepened, revealing the potential of pre-Y90-RE peripheral blood mononuclear cell (PBMC) immune profiling in predicting patient prognosis. Hepatology Digest invited Dr. Lin Zhang from Beijing Tsinghua Changgung Hospital to interpret a study published in Gut (IF=23), which explores the immune activation mechanisms of Y90-RE.
SIFIC Insights: “The Essential Growth Path for Infection Control Professionals” & “Supporting the Future of China’s Infection Control Field”

SIFIC Insights: “The Essential Growth Path for Infection Control Professionals” & “Supporting the Future of China’s Infection Control Field”

The 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Challenging Infectious Diseases (OFCID) and the Academic Corference of Global Chinese Association of Clinical Microbiology & Infectious Diseases (SIFIC 2024 "National Infection Control and Challenging Infectious Diseases" Combined Conference), was grandly inaugurated in Shanghai. "Xiaoshi," a reporter from Infection Medical Line, interviewed some of the participants at the SIFIC event, sharing the growth journey and bright future of SIFIC.
Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

On July 26, 2024, the highly anticipated 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Complex Infectious Diseases (OFCID) and the Annual Meeting of the Global Chinese Society of Clinical Microbiology and Infectious Diseases, was grandly inaugurated at the Shanghai International Conference Center. Themed "Precision Diagnosis, Precision Control," this year's conference aims to enhance the scientific and precise approach to infection prevention and control in China. Marking SIFIC's 20th anniversary, the conference not only reflected on past achievements but also looked forward to the boundless possibilities in the field of infection control, inspiring every participant to move forward together in writing a new chapter for infection prevention and control.
Emerging Perspectives: July Literature Digest (Part 2)

Emerging Perspectives: July Literature Digest (Part 2)

In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!
ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

For many years, platinum-based chemotherapy has been the standard treatment for metastatic urothelial carcinoma. However, this year’s EV-302/KEYNOTE-A39 study results, published in the New England Journal of Medicine (NEJM), demonstrated that the combination of enfortumab vedotin and pembrolizumab (EV+P) significantly improves survival outcomes for patients with locally advanced or metastatic urothelial carcinoma. The 2024 ASCO Breakthrough conference, held from August 8-10 in Yokohama, Japan, presented the efficacy and patient-reported outcomes (PROs) from the KEYNOTE-A39 study. Here is a summary for our readers.
ASCOBT24 | Evolving Treatment Prospects for mHSPC and Optimizing Cabazitaxel Benefit in mCRPC Patients

ASCOBT24 | Evolving Treatment Prospects for mHSPC and Optimizing Cabazitaxel Benefit in mCRPC Patients

The ASCO Breakthrough Summit, co-hosted by the American Society of Clinical Oncology (ASCO), the Japanese Society of Clinical Oncology (JSCO), and the Japanese Society of Medical Oncology (JSMO), in collaboration with several authoritative societies in the Asia-Pacific region, including the Chinese Anti-Cancer Association (CACA) and the Chinese Society of Clinical Oncology (CSCO), was held from August 8-10 in Yokohama, Japan. This year’s conference featured two significant advances in prostate cancer research (Abstract Nos. 118 and 119), which are summarized below.
2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

2024 CUDA | Dr. Qiang Wei: Precision Medicine Opens a New Chapter in Prostate Cancer Patient Benefits

In the spirit of "Healthy China, Urology First," the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was grandly held in Xi'an, Shaanxi Province, from August 8th to 11th, 2024. The event showcased the latest achievements in urological medicine from a global and multidimensional perspective. In recent years, with the deepening of molecular exploration, prostate cancer treatment has entered the era of precision medicine. Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University, to discuss the significance, recent breakthroughs, and future applications of precision medicine in prostate cancer.
2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

2024 CUDA | Dr. Shun Zhang: Standardizing the Management of Prostate Cancer Bone Metastases to Maximize Patient Benefits

Prostate cancer is one of the most common malignant tumors in the male urinary system, with over 110,000 new cases diagnosed annually in China. The bones are the primary site of metastasis for prostate cancer, leading to bone-related events (BREs) such as pathological fractures, spinal cord compression, and bone pain, which significantly impact patients' quality of life and long-term prognosis. Studies have shown that 60%-75% of prostate cancer patients with bone metastases experience severe bone pain at diagnosis, causing substantial disruption to their daily lives. Bone-related events, represented by bone pain, accompany the entire course of disease progression in prostate cancer bone metastasis patients, imposing a heavy economic burden on patients, families, and society. Urology Frontier has invited Dr. Shun Zhang from Medical School of Nanjing University Affiliated Nanjing Drum Tower Hospital to share insights on this topic.